Amneal Pharmaceuticals Inc. Class A (NYSE: AMRX) stock closed at 4.35 per share at the end of the most recent trading day (a 2.59% change compared to the prior day closing price) with a volume of 769.38K shares and market capitalization of 1.33B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 5500 people. Amneal Pharmaceuticals Inc. Class A CEO is Chintu Patel / Chirag Patel.

The one-year performance of Amneal Pharmaceuticals Inc. Class A stock is 62.45%, while year-to-date (YTD) performance is 118.59%. AMRX stock has a five-year performance of -75.44%. Its 52-week range is between 1.24 and 4.74, which gives AMRX stock a 52-week price range ratio of 88.86%

Amneal Pharmaceuticals Inc. Class A currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 1.13, a price-to-sale (PS) ratio of 0.21, a price to cashflow ratio of 2.20, a PEG ratio of -0.10, a ROA of -3.65%, a ROC of -1.40% and a ROE of -44.42%. The company’s profit margin is -15.53%, its EBITDA margin is 6.00%, and its revenue ttm is $1.60 Billion , which makes it $10.58 revenue per share.

Of the last four earnings reports from Amneal Pharmaceuticals Inc. Class A, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.10 for the next earnings report. Amneal Pharmaceuticals Inc. Class A’s next earnings report date is -.

The consensus rating of Wall Street analysts for Amneal Pharmaceuticals Inc. Class A is Moderate Buy (1.8), with a target price of $5.25, which is +20.69% compared to the current price. The earnings rating for Amneal Pharmaceuticals Inc. Class A stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amneal Pharmaceuticals Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amneal Pharmaceuticals Inc. Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 16.20, ATR14 : 0.22, CCI20 : 28.99, Chaikin Money Flow : 0.06, MACD : 0.10, Money Flow Index : 52.64, ROC : 4.82, RSI : 54.21, STOCH (14,3) : 54.17, STOCH RSI : 0.34, UO : 48.24, Williams %R : -45.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amneal Pharmaceuticals Inc. Class A in the last 12-months were: Alva Emily (Option Excercise at a value of $0), Anastasios G. Konidaris (Option Excercise at a value of $0), Andrew S. Boyer (Option Excercise at a value of $0), Boyer Andrew (Option Excercise at a value of $0), Boyer Andrew (Sold 29 302 shares of value $121 017 ), Deborah Autor (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), Jason B. Daly (Sold 0 shares of value $0 ), Kiely John (Option Excercise at a value of $0), Nark Ted (Option Excercise at a value of $0), Nikita Shah (Option Excercise at a value of $0), Patel Gautam (Option Excercise at a value of $0), Shah Nikita (Option Excercise at a value of $0), Yanai Shlomo (Option Excercise at a value of $0)